Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy Insights From the ODYSSEY-HCM Trial

Journal:

Journal of the American College of Cardiology

Published:

2025-08-28

DOI:

10.1016/j.jacc.2025.08.017

Affiliations:

22

Authors:

24

Go to article

Institutions	Authors	Share
Cleveland Clinic, United States of America (USA)	4.000000	0.17
Bristol-Myers Squibb, United States of America (USA)	4.000000	0.17
Medical University of Graz (Med Uni Graz), Austria	1.000000	0.04
Hospital Universitario A Coruña (CHUAC), Spain	1.000000	0.04
Chaim Sheba Medical Center at Tel HaShomer, Israel	1.000000	0.04
UCL, United Kingdom (UK)	1.000000	0.04
Kochi Medical School Hospital, Japan	1.000000	0.04
Heidelberg University Hospital at Medical Faculty Heidelberg, Uni Heidelberg, Germany	1.000000	0.04
Dante Pazzanese Institute of Cardiology, Brazil	1.000000	0.04
Inha University Hospital, Inha University, South Korea	1.000000	0.04
Duke University, United States of America (USA)	1.000000	0.04
Hospital da Senhora da Oliveira - Guimarães, Portugal	1.000000	0.04
Institute of Cancer of São Paulo (ICESP), Brazil	1.000000	0.04
IRCCS Meyer Children's Hospital, Italy	1.000000	0.04
University of San Francisco (USF), United States of America (USA)	1.000000	0.04
University of Pennsylvania (Penn), United States of America (USA)	1.000000	0.04
Biomedical Research Networking Centers (CIBER), Spain	0.833333	0.03
Hospital Universitario Puerta de Hierro Majadahonda, UAM, Spain	0.500000	0.02
La Fe University Hospital, Spain	0.333333	0.01
University of Valencia (UV), Spain	0.333333	0.01

Interested in Cardiovascular Medicine and Haematology?